Skeptic Graph · The Organism-Metabolite Tension
Is more Clostridium sporogenes always better?
No. This is the single most important qualification this site makes, and it deserves its own page rather than a footnote. Giving mice the bacterium and giving mice (or associating humans with) the molecule it makes are two different experiments with, in the literature reviewed here, two different directions of effect.
Animal The organism: an unfavourable mouse result
- Du L, et al. (2024), Microbiology Spectrum, PMID 38916334 — six weeks of direct oral Clostridium sporogenes supplementation in mice.
- Result: increased body weight, fat mass, adipocyte size, serum triglycerides, and hepatic lipogenesis gene expression — via enhanced intestinal energy, carbohydrate and fatty-acid absorption.
- Feed intake was unchanged — the effect was on absorption efficiency, not appetite.
HumanAnimal The metabolite: favourable associations and animal effects
- Higher serum 3-IPA associates with lower incident type 2 diabetes in the Finnish Diabetes Prevention Study (de Mello et al., 2017).
- 3-IPA treatment improved glucose tolerance and Akt phosphorylation in mice (Ballanti et al., 2024, mouse arm).
- Lower 3-IPA associates with worse liver fibrosis and cardiovascular disease markers in separate human cohorts.
The skeptic's questions, answered directly
Claim: Clostridium sporogenes probiotic supplementation is risk-free and beneficial for humans
- How do you know?
- You don't — no human C. sporogenes-supplementation trial exists. This claim is included specifically because it is unresolved, not because it is supported.
- Evidence for caution
- Du et al. 2024 (PMID 38916334): the adipogenesis/triglyceride result above, in mice.
- A complicating counterpoint
- Krause et al. 2024 (PMID 39397690): C. sporogenes-derived metabolites protected mice against colonic inflammation — a different endpoint (inflammation, not adiposity), in a different model. This does not contradict Du 2024 so much as show the outcome depends heavily on which endpoint and which model is examined.
- Limitations
- Both are mouse studies. Dose, strain and background diet were not systematically compared across the two papers.
- What would resolve it
- Matched-dose, matched-diet C. sporogenes-supplementation studies measuring both adiposity/glucose endpoints and inflammation endpoints in the same animals — and, eventually, a human trial.
- Not established
- Whether C. sporogenes probiotic supplementation is net-beneficial, net-harmful, or context-dependent for human metabolic health. Genuinely unresolved — this site says so plainly rather than defaulting to a flattering narrative because the organism is the central subject here.
Claim: raising 3-IPA causes better glucose regulation in humans
- How do you know?
- The Finnish Diabetes Prevention Study (de Mello et al., 2017) is a prospective cohort showing association, not a causal experiment.
- Alternative explanation
- 3-IPA could be a marker of a fibre-fermenting, tryptophan-processing gut ecosystem that itself associates with a healthier diet and better metabolic health, rather than a causal agent in its own right. The Stickland pathway needs substrate (dietary aromatic amino acids) and a fermentation-capable microbiome, so 3-IPA level plausibly tracks overall diet quality independent of any causal effect of 3-IPA itself.
- What would resolve it
- A randomized trial administering 3-IPA (or an effective 3-IPA-raising intervention) with glucose/insulin endpoints. None was located in this search.
- Falsifier
- An adequately powered RCT raising 3-IPA with no effect on glucose/insulin endpoints.
- Not established
- That raising 3-IPA causes improved glucose regulation in humans, or that taking 3-IPA or C. sporogenes lowers diabetes risk in people.
The trial-status ledger, restated plainly
| Claim | Status | Search record |
|---|---|---|
| A registered trial administers 3-IPA itself to humans | THREE FOUND — corrected 2026-09-10 | ClinicalTrials.gov API v2, re-run 2026-09-10: NCT06674018 (completed pilot), NCT07105514 (recruiting pilot follow-up) and NCT07318129 (recruiting, relapsing-remitting multiple sclerosis) — all Glostrup University Hospital, Copenhagen, none with a diabetes endpoint. The 2026-09-05 reading previously recorded here (zero matching trials) is superseded; both dated records on the Evidence Ledger |
| A trial administers something else and measures 3-IPA as an outcome | One found | NCT07739602 — Cornelian cherry fruit lyophilizate vs. placebo; fecal 3-IPA is a secondary outcome; completed, results not posted |
The name-collision problem
Search "IPA" on its own and the metabolite is not what you will find first. Wikipedia's own IPA disambiguation page ranks isopropyl alcohol, India Pale Ale (the beer style), the International Phonetic Alphabet, the Independent Practice Association (a US healthcare structure) and Ingenuity Pathway Analysis (bioinformatics software) all ahead of 3-indolepropionic acid for the bare abbreviation. That is exactly why every page on this site leads with the full chemical name and treats "IPA" strictly as a defined second-reference shorthand.
Can I buy 3-IPA, and would it do anything?
3-IPA is sold almost exclusively through research-chemical suppliers — Thermo Scientific, MedChemExpress, Fisher Scientific and similar — at laboratory-reagent purity, not as a consumer supplement. That is itself a useful, honest answer: the only human-administration trials on record are the three Glostrup research studies named above (registry re-run 2026-09-10), none with results posted, and no company sells a consumer 3-IPA product backed by a published human-outcome trial. One commercial biomarker-testing product offers to measure a person's 3-IPA level; that is a measurement service, not evidence that changing the number does anything. Given the organism-vs-metabolite tension above, "take more C. sporogenes instead" is not a substitute answer either — it swaps one open question for another.
What this page is not saying: it is not saying Clostridium sporogenes is dangerous, or that 3-IPA is worthless. The mechanistic, animal and cohort evidence for 3-IPA is genuinely substantial (see the Evidence Ledger). What this page insists on is precision: an association is an association, an animal result is an animal result, and the organism is not the molecule. That precision is the whole point of building this site around six separate evidence tiers instead of one confident paragraph.
Frequently asked
Is Clostridium sporogenes safe to take as a probiotic?
Unresolved. No human probiotic-safety trial of Clostridium sporogenes was located, and a 2024 mouse study found that direct oral supplementation with the organism increased fat mass, adipocyte size and serum triglycerides via enhanced energy absorption over six weeks, despite unchanged feed intake — a metabolically unfavourable direction that has not been tested against in humans.
If Clostridium sporogenes makes a beneficial metabolite, is more of the bacterium always better?
No. Giving mice the bacterium itself (Du et al., 2024) produced a different, unfavourable result from giving mice or associating humans with the molecule (3-IPA) it makes. The organism and the metabolite are not interchangeable claims, and no human evidence currently resolves whether Clostridium sporogenes supplementation is net-beneficial, net-harmful, or context-dependent.
Can I buy 3-IPA (indole-3-propionic acid) as a supplement?
It is sold almost exclusively through research-chemical suppliers as a laboratory reagent, not as a consumer supplement, and the only clinical trials that have administered it to humans are three Glostrup University Hospital research studies (NCT06674018, a completed pilot; NCT07105514, a recruiting follow-up pilot; NCT07318129, recruiting in multiple sclerosis — registry checked 2026-09-10), none of them for a diabetes outcome. Anyone considering it should know that basic fact before anything else.
